Lawsuits Challenge FDA Oversight of Evolving Spinal Cord Implants

The legal action targets Abbott Laboratories, Boston Scientific, Medtronic, and Nevro, focusing on spinal cord stimulator systems that plaintiffs argue have been fundamentally altered since their original 2001 FDA approval. Attorneys contend that manufacturers repeatedly utilized the FDA's premarket approval supplement process to introduce hundreds of changes—ranging from software and battery systems to wireless frequencies—without conducting new safety or efficacy trials. This practice allegedly allows companies to market devices as FDA-approved despite their material divergence from the original, tested version.

Patients report a consistent pattern of complications, including painful electric shocks, infection, device malfunctions, and the necessity for corrective surgeries. Behram Parekh, an attorney at Wisner Baum, stated that the current regulatory framework fails to keep pace with these cumulative modifications. He argues that the FDA lacks the resources to adequately examine the impact of these changes, creating a gap between patient expectations of non-opioid pain relief and the reality of the hardware implanted in their bodies. The firm points to the Australian Therapeutic Goods Administration as a potential model, noting that the agency recently restricted device use and mandated clinical follow-up studies following a similar post-market review.